The basal-like subgroup encompasses endometrial cancers with aggressive clinico-pathological features and correlates with frequent alterations of epigenetic regulators, including both mutations in trithorax group genes and overexpression of the two key polycomb genes, EZH2 and CBX2. This application of lncRNA profiling can potentially be utilized as a tool for clinical outcome prediction and targeted therapy selection. Here, EZH2 is linked to endometrial cancer.